title: Polypharmacy (or polytherapy) in the treatment of heart failure.
abstract: There is now conclusive evidence that most patients with heart failure due to left ventricular systolic dysfunction should be treated with angiotensin converting enzyme (ACE) inhibitors and beta-blockers. They will also need diuretics for the control of fluid retention. There is also a powerful case for adding spironolactone to the treatment of patients with more severe symptoms. Many doctors would also use digoxin and, especially if coronary disease is present, aspirin or warfarin. Most patients also have other chronic diseases, such as diabetes, arthritis, depression and dyspepsia, and each of these may provoke the prescription of yet another agent. Many patients will receive prescriptions to treat the side-effects of their therapy. Finding a sure path through the morass of pharmacotherapy is a daunting task. Polypharmacy is having a negative impact on new drug research in an area where there are in fact remarkably few really effective treatments and the therapeutic problem is only partially solved. This paper discusses some of the issues surrounding polypharmacy in heart failure and how to resolve them, using an illustrative case history. It highlights the potential benefits of polypharmacy with effective drugs and the gross over-use of ineffective treatments in heart failure. The major problem with polypharmacy in heart failure is not the heart failure treatment itself, but the drugs for other concomitant conditions, the effectiveness of which is often not supported by an appropriate evidence base and for which alternative, less noxious management strategies often exist. Polypharmacy may be deleterious not only because of the increased potential for side-effects and drug interactions but also because taking unnecessary therapy reduces compliance with effective drugs.
authors.affiliation: Department of Cardiology, University of Hull, UK.
authors.forename: J G
authors.initials: JG
authors.lastname: Cleland
authors.forename: A
authors.initials: A
authors.lastname: Baksh
authors.forename: A
authors.initials: A
authors.lastname: Louis
mesh_terms: D002317:Cardiovascular Agents / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis / Q000191:economics; D006333:Heart Failure / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D006801:Humans; D019338:Polypharmacy; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents